Our analyses revealed that 293C3-SDIE is well suited to target CD133 expressing CRC cells for NK cell ADCC because 293C3-SDIE showed convincing binding characteristics in CRC and potently induced anti-tumor immunity as determined in multiple experimental settings using CRC cell lines and NK cells contained in PBMC from healthy donors as effector cells. This evidence concerns the gene PROM1 and neoplasm.